Digital Biomarkers Market Size, Patient Volume, Treatment Adoption Rates, Pricing Analysis, Regulatory Landscape, Clinical Trial Trends, Market Share, and Demand Forecast

Revenue, 2025

USD 5.04 Bn

Forecast Year, 2035

USD 36.98 Bn

CAGR, 2026 - 2035

22.05%

Report Coverage

Global

What is the Digital Biomarkers Market Size?

The global digital biomarkers market size is calculated at USD 5.04 billion in 2025 and is predicted to increase from USD 6.19 billion in 2026 to approximately USD 36.98 billion by 2035, expanding at a CAGR of 22.05% from 2026 to 2035. The market growth is propelled by rising chronic diseases, a focus on investment in digital healthcare, and government initiatives for scaling digital monitoring.

Market Highlights

• North America dominated the digital biomarkers market with the largest market share of 58.45% in 2025.
• Asia Pacific is expected to expand at a double digit CAGR of 23.52% during the forecast period.
• By end-use, the healthcare companies segment contributed the biggest market share of 50.18% in 2025.
• By end-use, the payers segment is projected to grow at a solid CAGR of 24.5% during the forecast period.
• By clinical practice, the diagnostic digital biomarkers segment contributed the highest market share in 2025.
• By system component, the data collection tools segment led the market in 2025.
• By system component, the data integration systems segment is likely to experience the fastest growth during the forecast period.
• By application, the cardiovascular diseases segment held the largest market share in 2025.

Market Overview

The digital biomarkers market is a crucial segment of the life sciences industry. This industry deals in developing digital biomarkers for manufacturing different medicines. There are different types of components used in this industry comprising of mobile apps, wearable, digital platforms, biosensors, desktop-based software and some others. There are various kinds of biomarkers available in the market consisting of diagnostic digital biomarkers, monitoring digital biomarkers, predictive and prognostic digital biomarkers and some others. These biomarkers are used in various therapeutic areas including cardiovascular and metabolic disorders (CVMD), respiratory disorders, psychiatric disorders, sleep & movement disease, neurological disorders, musculoskeletal disorders and some others. This industry comprises of several end-users such as Healthcare Companies, Healthcare Providers, Payers and some others.

What is the role of AI in Digital Biomarkers Market?

AI has transformed the landscape of the overall healthcare industry. The biomarker companies have started developing AI-based platforms for deriving information of health. In genomics sector, AI algorithms including convolutional neural networks (CNNs) helps in decoding genomic sequences, identifying variations with precision for developing novel medicines. In proteomics, AI enhances mass spectrometry-based protein analysis that improves the process involved in drug discovery. In epigenetics, AI helps in identifying different diseases and enhances chromatin accessibility and histone modifications that are integral for biotech companies. Thus, AI plays a transformative role in the positively shaping the digital biomarkers market.

• In June 2024, BioAI collaborated with Genomic Testing Cooperative (GTC). This collaboration is done to utilize AI technology for discovery of novel biomarker.

Digital Biomarkers Market Growth Factors

• The rising uses of the digital biomarkers in various application areas such as diabetes, respiratory diseases, CVDs, and sleep disorders.
• The rising investments in the research and development of drugs are resulting in the increased cost of the drugs.
• The growing prevalence of chronic diseases and growing geriatric population across the globe is fueling the demand for the digital biomarkers.
• The increasing usage of health informatics in the healthcare industry.
• The necessity of the patients to regularly monitor their health conditions and have consultations from doctors.
• Digital biomarkers can provide cost-effective and personalized treatment to ensure efficient patient care.
• The various developmental strategies adopted by the market players to develop advanced digital biomarkers.
• The rapid development of the telecommunications and the IT infrastructure

Digital Biomarkers Market Trends

• Stretching Variety to Develop Innovations: As the sector shifts forward to place higher importance on biomarker datasets, inclusive research will demand the ideal showcases of disease variability and the real-world patient populations. This growth makes discoveries and improves their potential to grow more accurate, focused therapies that are aligned with the demands of more individuals.
• Multi-Omics for a More Overall Biological Background: By mixing several layers, scientists can take a more overall picture of a disease biology. Instead of checking out a single molecule, known as a "snapshot", multi-omics allows a system-level alignment of how proteins, genes, and other biomarkers communicate.
• Liquid Biopsy and the move towards Noninvasive Tracking: The move towards less invasive sampling has opened the possibilities for more frequent data collection, which makes larger datasets and the possibility for developing accurate medicine. This strategy enables clinicians and researchers to track diseases more significantly and check updates in real time.
• The Emergence of Virtual Health Modelling: By lowering manual data entry and avoiding human error, it develops confidence in downstream analysis. The electronic capture machines enable real-time data validation, which assists by ensuring consistency, completeness, and traceability are present across clinical paces.

Trade Analysis

• As per the global biomarker import data, between June 2024 and May 2025, the buyers have globally imported 55 shipments of biomarkers.
• Such shipments were being assisted by 55 exporters and bought by 66 official worldwide buyers, which has shown a 13% development as compared to the last one-year period.
• Vietnam, Singapore, and Colombia have come up as the leading three biomarker-importing countries.
• The United States, China, and Vietnam are the leading 3 exporting countries.
  (Source: https://www.volza.com)
• United States has shipped 264 shipments, followed by China with 83 shipments, and lastly by Vietnam with 68 shipments, which have ranked as the biggest worldwide biomarker exporters.
  (Spurce: https://www.volza.com)

Market Outlook

What's Driving the Rapid Increase of the Global Digital Biomarkers Industry?

• Industry Growth Overview: Increased usage of remote patient monitoring (RPM), decentralized clinical trials (DCT), and real-time disease monitoring driven by advanced artificial intelligence (AI) technology and regulatory recognition for using digital endpoints across medicine is increasing the overall growth of this market.
• Sustainable Trends: Digital biomarkers support a more sustainable healthcare model by creating fewer hospital visits, lowering the costs of diagnosis, and creating less resource-intensive clinical trials, allowing for long-term remote monitoring with both reduced environmental impact and reduced operational costs.
• Global Growth: The rapid global growth of digital biomarkers is being driven by an increasing number of smartphone users and the development of comprehensive telemedicine platforms in emerging markets, which have improved access to and use of telemedicine services.

Digital Biomarkers Market Scope

Market Dynamics

Driver

Regulatory Flexibility Towards Digital Health Solutions Drives the Industry

For digital biomarkers, FDA has employed more than approach in order to increase the number of products in the market. For instance, the agency has modified its guidelines regarding the software as-medical-device (SaMD). This agency has also launched a pre-certification program, PreCert. As per the program, FDA would approve the company and not the product manufactured by it. By this program, the agency aims to improve the entry process of a company in the market and add in product modification process of the company. Other than the new initiatives, the agency has also revised its stand on digital health tools and FDA's Center for Devices and Radiological Health has made a committee solely focused on the software solutions. Thus, the regulatory flexibility towards digital health solutions is anticipated to boost the growth of the digital biomarkers market.

Restraint

Data Security Issues along with Sample Collection Issues Hampers the Industry

The digital biomarkers market faces several issues in their daily operations. Firstly, there are various security related issues related to biomarkers that creates negative impact in the industry. Secondly, numerous problems arise in sample collection and processing. Thus, these factors are expected to restrain the growth of the digital biomarkers market.

Opportunity

Rapid Adoption of Wearables and Advancements in Sensors to Shape the Upcoming Days

The popularity of wearables among people has gained traction in recent times. These wearables are used for generating real-time health data which can be further translated into digital biomarkers. It is also used for evaluating the efficacy and/or safety of any medical intervention. Moreover, numerous technological advancements in medical sensors are useful for various applications such as data collection, data analysis, digital biomarker fingerprint. Thus, rising adoption of wearables and technological advancements in sensor technology is expected to create ample growth opportunities for the companies in the future.

Segments Insights

System Component Insights

What Made the Data Collection Tools Segment Dominate the Digital Biomarkers Market?

The data collection tools segment led the market in 2025 because of the evolution of remote healthcare and preventive medication, driven by wearable sensors, mobile apps, smart devices, and connected medical tools. This system component enhances sensor precision, extends battery life, and strengthens wireless connectivity, thereby increasing both the quality and volume of real-world health data. As healthcare providers and researchers increasingly depend on long-term patient data for personalized treatments and research, the adoption of advanced data collection tools in digital health is emphasised.

The data integration systems segment is projected to grow at the fastest rate in the upcoming years, due to the clinical sector's focus on unifying scattered health data for a healthier heart rate. These systems gather data from wearables, diagnostics, EHRS, genomics, and patient responses to create detailed monitoring. The demand for interoperability, data security, and platform compatibility is accelerating the adoption of AI solutions capable of processing high volumes of pathological data. Healthcare organisations need to invest in data integration systems that increase clinical decision-making and the accuracy of digital biomarkers.

Application Insights

How did the Cardiovascular Diseases Segment Dominate the Digital Biomarkers Market?

The cardiovascular diseases segment dominated the market in 2025, driven by rising heart disorder cases and the need for cardio risk monitoring. Digital biomarkers offer real-time physiological data, enabling primary intervention and superior cardiovascular disease management. Healthcare systems value digital biomarkers for reducing hospital visits and improving long-term outcomes, aligning with the growth of wearable cardiac devices and analytics, which are shifting care toward prevention.

The respiratory disease segment is experiencing the fastest growth in the market during the forecast period because digital biomarkers enhance the management of chronic lung conditions through continuous real-time monitoring. The rising urban population, pollution, and ageing populations have increased respiratory illnesses, highlighting the need for scalable monitoring. Respiratory metrics tools that track breathing patterns, coughs, oxygen levels, and asthma to detect disease progression. Integrating digital biomarkers into remote lung care to detect deterioration and enable timely intervention by maintaining healthcare efficiency.

Clinical Practice Insights

Which Clinical Practice Segment Dominated the Digital Biomarkers Market?

The diagnostic digital biomarkers segment held the highest market share in 2025, attributed to offering objective, data-driven disease detection, in which digital biomarkers continuously monitor physiological and biological signals that indicate disease health status. In clinical practice, integrating machine learning and analytics improves neurological function and pattern detection, enhancing diagnostic accuracy. The expanding demand for initial disease detection, combined with personalized, non-invasive treatments, drives clinical providers to adopt digital biomarkers to optimize treatment.

The monitoring digital biomarkers segment is expected to witness rapid growth over the forecast period, driven by its ability to provide continuous fitness, metabolic monitoring, and real-time health assessments. They offer insights into disease progression, treatment outcomes, and pathway changes by collecting real-time health data. Healthcare providers use digital biomarkers to manage chronic diseases, support recovery, and improve medication adherence. As healthcare moves toward value-based care, the capacity of digital monitoring biomarkers to support proactive management, lower costs, and boost patient engagement drives substantial development.

End Use Insights

Which End Use Segment holds the Largest Share in the Digital Biomarkers Market?

The healthcare companies segment dominated the digital biomarkers market in 2025, supported by the therapeutic, biotechnology, medical devices, and digital well-being sectors, which are approving digital biomarkers for innovation. The focus on patient-centred care and data-driven results boosts significant investment in digital health platforms and patient analytics. The healthcare industry is shifting towards improving clinical trials, collecting real-world data, monitoring outcomes, and accelerating development through strategic alliances between technology developers and healthcare providers across commercial and research fields

The payers segment is experiencing the fastest growth in the market during the forecast period, driven by requirements to improve healthcare and provide high temporal resolution. Financers use digital biomarkers to assess patient outcomes, treatment adherence, and disease progression, enabling more accurate risk assessment and better care planning. Digital biomarkers support earlier interventions and resource efficiency, promoting payers to enhance operational efficiency and build sustainable healthcare systems. The move towards value-based reimbursement advances demand for objective health data to measure outcomes and performance.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing. The various developmental strategies like acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Regional Insights

North America dominated the digital biomarkers market with the largest market share of 58.45% in 2025.

The increased healthcare expenditure along with the presence of huge geriatric population in the developed market such as U.S. and Canada is augmenting the adoption of the digital biomarker in the North American healthcare industry. The higher adoption rate of digital technologies in North America has significantly driven the market growth.

What is the U.S. Digital Biomarkers Market Size?

The U.S. digital biomarkers market size was evaluated at USD 2 billion in 2025 and is predicted to be worth around USD 14.84 billion by 2035, rising at a CAGR of 22.19% from 2026 to 2035.

U.S. Market Growth Trends

The U.S. market is rapidly increasing, driven by advanced healthcare and domestic-scale digital health adoption. The country's biomedical investments are especially in wearable technology, healthcare analytics, and clinical research, which are boosting domestic growth. Rising demand for personalized medicine, remote monitoring, and distributed trials increases digital biomarker use across the United States. The tech suppliers and life sciences firms focus on collaboration to enhance innovation and maintain U.S. dominance in digital biomarker solutions.

In USA, the presence of several digital biomarker companies such as BrainStorm Cell Therapeutics, Amgen Inc. and Empatica Inc. has boosted the market growth. Moreover, there are several research institutes involved in medicine discovery that increases the demand for digital biomarker, thereby fostering the industrial expansion.

• In April 2024, BrainStorm Cell Therapeutics Inc announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve.

Asia Pacific is expected to expand at a double digit CAGR of 23.52% during the forecast period.

The increased government expenditure on the development of the strong and advanced healthcare infrastructure in the region in the past few years has significantly boosted the adoption of the digital biomarkers in the Asia Pacific market. The proliferation of the digital technologies and its increasing adoption in the healthcare sector in Asia Pacific is fueling the growth of the market. Moreover, the presence of huge population and rising prevalence of chronic diseases along with the growing geriatric population is expected to exponentially augment the demand for the digital biomarkers in the foreseeable future.

China Market Growth Trends

China's market is experiencing continuous advancement through digitalisation practices and increased AI healthcare investments. Government initiatives in the healthcare sector support digital biomarker platforms across clinical and consumer health. Domestic demand for connected devices, monitoring, and higher healthcare spending. China's large population and growing chronic diseases create opportunities for greater preventive health awareness and scalable digital monitoring.

Europe: Innovative Digital Health Regulation Driven by Regulation

On Europe's shores, a strong data protection framework, along with the existence of a national digital health strategy, and the large adoption of digital endpoints are driving the growth of the digital health market in Europe. Large-scale validation projects are being developed through collaboration between public and private stakeholders.

Germany Market Growth Trends

Germany's market is projected to grow steadily, influenced by a strong healthcare system and advanced research infrastructure. Country-driven digital health initiatives allow providers to increasingly use digital biomarkers for patient monitoring and precision medicine. Germany's focus on innovation and evidence-based practices facilitates investments in biomarker technology, boosting the manufacturing of digital therapeutics, wearable tech, and data analytics, thereby promoting domestic expansion.

Latin America: Mobile First Healthcare Transformation

Due to a high mobile penetration and a growing rate of adoption of telemedicine solutions, Latin America is benefiting from a high volume of deployable smartphone-based digital biomarkers across all facets of healthcare, particularly in the areas of chronic care management & mental health management.
Brazil is generating substantial annual growth rates from a high focus on digitization activities and investment in private health technologies.

Brazil Market Growth Trends

Brazil's market is growing as healthcare providers implement digital solutions to improve access to care, manage chronic illnesses, and optimize resources. The healthcare providers focus on continuous patient monitoring and data-driven care to improve the cure rate and reduce costs across Brazil. The rising demand for smartphones, better internet, and telehealth, along with public and private investments that support the use of digital biomarkers, positions Brazil as a major market for digital biomarker innovation.

Middle East and Africa (MEA): Expansion of Smart Healthcare Technology

The overall expansion of the MEA Region has been driven by an overall growth in smart hospital projects, increased adoption of government-led digital health reforms, and increased utilization of wearable technologies for population health monitoring and the activity-based management of chronic diseases.
Within the UAE, there has been significant investment into the development of AI-based platforms for healthcare, including but not limited to precision medicine initiatives.

UAE Market Growth Trends

The UAE market is growing due to healthcare modernization, digital innovation, and connected healthcare technologies. The supportive government initiatives in precision medicine, AI, and digital health are boosting the demand for advanced monitoring and driving awareness among hospitals across the UAE. The country's healthcare hub is expected to attract substantial investment in digital biomarker research and development and commercialization.

Government Initiatives

• In July 2026, the Ayushman Bharat Digital Mission constructed one of the globe's biggest digital health ecosystems, which has connected 104 health records to over 93 crore ABHA accounts. By avoiding paperwork and lowering the waiting period, ABDM is smoothly linking patients to hospitals, insurers, and doctors on an accurate, unified network.
  (Source: https://www.pib.gov.in)
• In January 2026, TDB officially signed a huge help for such a project named "Multiviral Constant Glucose Monitoring (CGM) Device that has cardiovascular biomarkers for early detection of heart conditions, along with Diabetes Monitoring. This project is being assisted under the Indo-Canada partnership with the Industrial Research & Development programme.
  (Source: https://www.pib.gov.in)

Investment Landscape

• In August 2025, Twin Health, which is an AI digital twin pioneer for the purpose of metabolic health, raised USD 53 M in funding, supported by Maj Invest of Denmark. The investment will develop Twin's growth among health plans and the Fortune 500 clients in healthcare, retail, technology, financial services, and manufacturing.
  (Source: https://www.prnewswire.com)
• In August 2025, California-based digital twin company for the aim of metabolic health, Twin Health, has gained USD 53 million in a Series E funding round supported by Maj Invest of Denmark, which brings its valuation to USD 950 million.
  (Source: https://www.mobihealthnews.com)
• In March 2026, Meddi, a Mexican healthtech company that concentrates on healthcare for insurance and the corporate industry, officially gained USD 8 million in funding from GNP Seguros with assistance of a stake in the brand.
  (Source: https://contxto.com)

Value Chain Analysis

• Data Generation and Device Level: Wearable devices, smartphones, implantable devices, and environmental sensors collect physiological and activity information such as heart rate variability, gait patterns, sleep patterns, and speech measures.
  Key Players: Apple, FitBit (Google), and Garmin.
• Data Processing, Analytics, and AI Integration: This is where clinicians convert the raw data into clinically relevant digital biomarkers. This occurs through the use of artificial intelligence algorithms and machine learning models, and through the use of signal processing technology.
  Key Players: Evidation Health, Koneksa, and Biofourmis.
• Clinical Validation, Deployment, and End User Integration: As a result of working with validated digital biomarkers, clinical trials have the ability to deliver these digital biomarkers to pharmaceutical research and development, payers, and providers in their normal workflow.
  Key Players: Roche, Novartis, and IQVIA.

The Principles and Certification Frameworks for Digital Biomarker

Clinical validation does not terminate with testing; it should match the discovered medical data rules and the regulatory frameworks that ensure interoperability, safety, and reproducibility. For digital biomarkers, such rules fill the gap between clinical credibility and innovative technology.

• Regulatory and Quality Frameworks: To receive clinical approval, digital biomarkers and their respective underlying systems should align with internationally recognized rules:
• ISO 27001: It concentrates on information security management, which is crucial for securing sensitive health data during storage and collection.
• ISO 13485: It specifies the demands for quality management systems in terms of medical device growth. It ensures consistent procedures for testing, design, and documentation.
• MDR (EU) & FDA Digital Health Framework (US): It regulates software as a medical device, known as SaMD, that checks whether a digital biomarker has officially passed as a diagnostic or tracking machine.
• GDPR & HIPAA Compliance: It defines consent and privacy frameworks that protect personal health information present across jurisdictions.
  Compliance with such frameworks has established a basis of traceability, trust, and security that shifts digital biomarkers into a certifiable medical-grade count.

Data Standards and Interoperability: For digital biomarkers to work smoothly across systems and devices, they should stick to classified data interoperability rules:

• SNOMED CT: It serves as a universal clinical terminology for consistent medical checking.
• LLINC (Logical Observation Identifiers Names and Codes): It organizes biomarker identifiers across health systems and laboratories.
• FHIR (Fast Healthcare Interoperability Resources): It fully defines how data can be shared between apps, EHRs, and devices in real time.
  (Source: https://www.precedenceresearch.com)

Competitive Landscape

The digital biomarkers market is advancing rapidly through technological innovation, strategic partnerships, and healthcare digitalization. The competition among pharmaceutical, device makers, software firms, and startups intensifies, driving innovation and digital integration in treatment products. Companies like Bayer AG, Medopad Ltd., and F. Hoffmann-La Roche Ltd. develop sensor platforms, AI analytics, and integrated digital health solutions to generate clinical insights by maintaining competitive pricing. The developmental strategies focus on clinical validity, regulatory compliance, interoperability, and scalable deployment of digital biomarkers.

Digital Biomarkers Market Companies

• Bayer AG
• Biogen Inc.
• ActigraphLLc
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Fitbit Inc
• GlaxoSmithKline Plc
• Koninklijke Philips N.V.
• Mindstrong Health
• Medical Care Corporation
• Medopad Ltd

Industry Leaders' Announcements

• In September 2024, Chris Benko, the CEO of Koneksa announced to provide biotech and pharma companies with real-time data sharing and analysis to check the validation and adoption of digital measures for deriving more data insights in clinical trials.
• In March 2024, Guilhem Dupont, the CEO of Indivi announced to develop biomarkers for treating patients suffering from multiple sclerosis.

Recent Developments

• In June 2026, Samsung Electronics formed a strategic partnership with Alcedis to improve clinical research using wearable device endpoints and digital biomarkers. The collaboration focuses on turning biometric data from wearables into relevant evidence for pharmaceutical research, enhancing efficiency, and promoting decentralized clinical research. (Source: https://www.samsungmobilepress.com)
• In May 2026, Herantis Pharma collaborated with Indivi to incorporate Indivi's digital biomarker platform into the Phase II clinical trial of HER-096 for Parkinson's disease. This partnership focuses on accurate detection of treatment effects with digital biomarkers to enhance clinical trial outcomes and accelerate neuroscience drug development. (Source: https://stifflersearch.com)
• In January 2026, Caris Life Sciences partnered with Everlywell to introduce Caris Detect™, a multi-cancer early detection (MCED) test through Everlywell's platform. This launch uses biomarker data and whole-genome sequencing to expand access to advanced cancer biomarker screening and facilitate earlier disease detection. (Source: https://www.prnewswire.com)
• In October 2024, Proscia launched Concentriq. Concentriq is an AI-based platform designed for discovering biomarkers to develop novel therapeutics.
• In September 2024, Roche announced partnership with Lunit. This partnership is done for enhancing precision medicine and improving cancer biomarker testing.
• In August 2024, Paige launched an AI-powered biomarker module. This biomarker module has the capability of evaluating around 505 genes and identifying 1,228 molecular biomarkers from a single pathology slide.

Segments Covered in the Report

By System Component

• Data Collection Tools
• Mobile Apps
• Wearable
• Digital Platforms
• Biosensors
• Desktop-Based Software
• Data Integration Systems

By Application

• Sleep & Movement Disease
• Cardiovascular Diseases
• Respiratory Disease
• Neurodegenerative Disorders
• Diabetes
• Gastrointestinal Disease
• Psychiatric Disorder
• Others

By Clinical Practice

• Diagnostic Digital Biomarkers
• Monitoring Digital Biomarkers
• Predictive And Prognostic Digital Biomarkers
• Other's (Safety, Pharmaco dynamics/ Response, Susceptibility)

By End-use

• Healthcare Companies
• Healthcare Providers
• Payers
• Others (Patient, caregivers)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa